US2006182743A1PendingUtilityA1

Methods of treating skin disorders using an IL-31RA antagonist

Assignee: BILSBOROUGH JANINEPriority: Feb 14, 2005Filed: Feb 14, 2006Published: Aug 17, 2006

Est. expiryFeb 14, 2025(expired)· nominal 20-yr term from priority

A61P 37/08A61P 37/02A61P 43/00A61P 35/00C07K 16/2866A61P 17/00C07K 14/7155A61P 17/10A61K 2039/505C07K 2317/24C07K 2317/76A61P 17/14A61K 39/00

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.

Claims

exact text as granted — not AI-modified

1 . A method of treating a patient suffering from a skin disorder, the method comprising:
administering a therapeutically effective amount of an anti-IL-31RA antibody or fragment to the patient, wherein the anti-IL-31RA antibody or fragment binds with amino acid residues 20-519 of SEQ ID NO:6 or portion thereof, or amino acid residues 33-532 of SEQ ID NO:8 or portion thereof, and wherein the anti-IL-31RA antibody or fragment prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus.

2 . The method of claim 1 wherein the anti-IL-31RA antibody is a polyclonal antibody.

3 . The method of claim 1 wherein the anti-IL-31RA antibody is a neutralizing monoclonal antibody.

4 . A hybidoma which produces a monoclonal antibody according to claim 3 .

5 . The method of claim 1 wherein the antibody fragment is a Fab fragment.

6 . The method of claim 1 wherein the antibody fragment is a Fab′ fragment.

7 . The method of claim 1 wherein the antibody fragment is a F(ab′)2 fragment.

8 . The method of claim 1 wherein the antibody fragment is a single chain Fv.

9 . The method of claim 1 wherein anti-IL-31RA antibody or fragment binds with amino acid residues 20-277 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8.

10 . The method of claim 1 wherein the anti-IL-31RA antibody or fragment binds with about 4-10 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.

11 . The method of claim 1 wherein the anti-IL-31RA antibody or fragment binds with about 10-14 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.

12 . The method of claim 1 wherein the anti-IL-31RA antibody or fragment binds with about 14-30 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.

13 . The method of claim 1 wherein the fragment is further conjugated to a polyethylene glycol.

14 . The method of claim 1 wherein the fragment is further conjugated to human serum albumin.

15 . A method of treating a patient suffering from a skin disorder, the method comprising:
administering a therapeutically effective amount of a soluble IL-31RA receptor to the patient, wherein the soluble IL-31RA receptor binds with an IL-31 polypeptide consisting of amino acid residues 1-164 SEQ ID NO:2, and wherein the soluble IL-31RA receptor prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus.

16 . The method of claim 15 wherein the soluble IL-31RA receptor comprises amino acid residues 20-519 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8.

17 . The method of claim 15 wherein the soluble IL-31RA receptor comprises amino acid residues 1-324 of SEQ ID NO: 10.

18 . The method of claim 15 wherein the soluble IL-31RA receptor comprises amino acid residues 1-239 of SEQ ID NO: 12.

19 . The method of claim 15 wherein the soluble IL-31RA receptor is further conjugated to the Fc region of IgG, IgA, IgD, IgM or IgE.

20 . The method of claim 15 wherein the soluble IL-31RA receptor is an IL-31RA homodimer.

21 . The method of claim 15 wherein the soluble IL-31RA receptor is an IL-31RA/OSMRbeta heterodimer.

22 . The method of claim 15 wherein soluble IL-31RA receptor binds with an IL-31 polypeptide consisting of amino acid residues 24-164 of SEQ ID NO:2.

23 . The method of claim 15 wherein soluble IL-31RA receptor binds with an IL-31 polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2.

24 . The method of claim 15 wherein the soluble IL-31RA receptor is further conjugated to a polyethylene glycol.

25 . The method of claim 15 wherein the soluble IL-31RA receptor is further conjugated to human serum albumin.

Join the waitlist — get patent alerts

Track US2006182743A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.